Inhibikase Therapeutics (IKT) Return on Sales (2020 - 2024)
Inhibikase Therapeutics' (IKT) quarterly Return on Sales came in at 204260.85% in Q3 2024, down 20426025.0% year-on-year from N/an in Q4 2023, and down 8444583.18% on a QoQ basis from 2.42% in Q2 2024.
Inhibikase Therapeutics (IKT) Return on Sales (2020 - 2024) Analysis & Trends
Inhibikase Therapeutics (IKT) has 5 years of Return on Sales data on file, last reported at 204260.85% in Q3 2024.
- On a quarterly basis, Return on Sales fell 20426025.0% year-over-year to 204260.85% in Q3 2024; TTM through Sep 2024 was 204260.85%, a 20426023.0% decrease from a year earlier, with the FY2023 full-year figure at 0.77%, up 170.0% from the prior year.
- Return on Sales for Q3 2024 stood at 204260.85%, down from 2.42% in the prior quarter.
- Over the last five years, Return on Sales for IKT reached as high as 0.02% in Q1 2021 and fell as low as 204260.85% in Q3 2024.
- Historically, Return on Sales has averaged 13070.69% across 5 years, with a median of 0.68% in 2022.
- Across the five-year window, Return on Sales jumped 2516 bps in 2022 and tumbled 20426025 bps in 2024, its largest moves.
- Year by year, Return on Sales stood at 0.07% in 2020, then sank by 36350 bps to 25.84% in 2021, then jumped by 97 bps to 0.68% in 2022, then sank by 6457080 bps to 44035.66% in 2023, then tumbled by 364 bps to 204260.85% in 2024.
- Per Business Quant data, the three most recent Return on Sales figures were 204260.85% in Q3 2024, 2.42% in Q2 2024, and 1.03% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 0.00% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -204,260.85% |
| Jun 30, 2024 | -2.42% |
| Mar 31, 2024 | -1.03% |
| Dec 31, 2023 | -44,035.66% |
| Sep 30, 2023 | -0.60% |
| Jun 30, 2023 | -0.54% |
| Mar 31, 2023 | -0.74% |
| Dec 31, 2022 | -0.68% |
| Sep 30, 2022 | -6.26% |
| Jun 30, 2022 | -7.08% |
| Mar 31, 2022 | -1.01% |
| Dec 31, 2021 | -25.84% |
| Sep 30, 2021 | -0.14% |
| Jun 30, 2021 | -0.02% |
| Mar 31, 2021 | -0.02% |
| Dec 31, 2020 | -0.07% |
| Sep 30, 2020 | -0.18% |
| Jun 30, 2020 | -0.02% |
| Mar 31, 2020 | -0.02% |